What we are studying
The goal of this outcomes study will be to continue monitoring safety but also to directly focus on clinical (symptoms and quality of life) and biochemical control (IGF-I and glucose). Specifically, data will be collected more systematically related to diabetes control and include additional data on PRO measurements. Data will be collected at baseline and at intervals in accordance with the standard management of patients with acromegaly and in accordance with the recommendations of the Somavert® (pegvisomant) Package Insert (US) or Somavert® (pegvisomant)